NF1 encodes a RAS GTPase-Activating Protein. Accordingly, aberrant RAS activation underlies the pathogenesis of NF1-mutant cancers. Nevertheless, it is unclear which RAS pathway components represent optimal therapeutic targets. Here we identify mTORC1 as the key PI3K effector in NF1-mutant nervous system malignancies and conversely show that mTORC2 and AKT are dispensable. However, we find that tumor regression requires sustained inhibition of both mTORC1 and MEK. Transcriptional profiling studies were therefore used to establish a signature of effective mTORC1/MEK inhibition in vivo. We unexpectedly found that the glucose transporter, GLUT1, was potently suppressed but only when both pathways were inhibited. Moreover, unlike VHL and LKB1 mutant cancers, reduction of 18 F-FDG uptake required the suppression of both mTORC1 and MEK. Together these studies identify optimal and sub-optimal therapeutic targets in NF1-mutant malignancies and define a non-invasive means of measuring combined mTORC1/MEK inhibition in vivo, which can be readily incorporated into clinical trials.
INTRODUCTION
The NF1 tumor suppressor is mutated or suppressed in a variety of sporadic cancers including glioblastoma, neuroblastoma, melanoma and non-small cell lung cancer (1-5).
NF1 mutations also underlie the familial cancer syndrome, neurofibromatosis type 1 (NF1) (6, 7) . NF1 patients exhibit a variety of tumorigenic and non-tumorigenic manifestations but the most common cause of death is malignant peripheral nerve sheath tumors (MPNSTs). These highly aggressive tumors are lethal in approximately 70% of patients, and conventional chemotherapy and radiation do not reduce mortality in individuals with inoperable tumors (8) (9) (10) . Therefore, developing effective targeted therapies for these individuals represents an important and unmet clinical need.
Moreover, an effective therapy for this tumor type may be more broadly applicable to other sporadic NF1-mutant cancers.
The NF1 tumor suppressor gene encodes a RAS GAP, which inactivates RAS by catalyzing the hydrolysis of RAS-GTP (6, 7) . As such, when NF1 is mutated or suppressed, RAS and downstream effectors become hyperactivated (11) . Both the PI3K/mTOR and MEK/ERK pathways have been shown to be important in various NF1-mutant tumors and therefore components of these pathways represent potential therapeutic targets (12-15). However, given the plethora of available drugs that target these pathways we set out to genetically and chemically deconstruct the most important signaling nodes in NF1-mutant MPNSTs. Together with preclinical studies in a genetically engineered mouse tumor model, we found that mTORC1 is the key PI3K pathway component in these NF1-mutant malignancies, AKT and TORC2 are Several combined PI3K/MEK pathway trials are in development or are being considered for other cancers (16) . However, the clinical challenge will be to identify a drug combination and dose that effectively suppresses both pathways, while minimizing toxicity. It is currently unclear how dosing can be adjusted while confirming that both targets are sufficiently inhibited in real time, especially given that the duration of inhibition appears to be an important determinant of efficacy. Thus, establishing a tractable biomarker for effective, combined target inhibition would greatly facilitate this effort. By performing transcriptional profiling and imaging studies we unexpectedly identified GLUT1, which mediates 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake, as a key gene that is suppressed prior to tumor regression but only when both pathways are effectively inhibited. Moreover, we show that 18 F-FDG uptake is a reliable readout of combined target inhibition. This insight can be directly applied to the design of clinical trials in NF1 mutant cancers and may also have broader utility in other RAS-driven tumors. We previously showed that loss or inactivation of NF1 triggers the aberrant activation of PI3K/mTORC1 signaling in human and mouse MPNSTs (17) . However, it is currently unclear which specific components within this pathway represent the best therapeutic targets. Such insight would reveal which drugs should be preferentially evaluated or excluded in clinical trials. Therefore, we sought to genetically and chemically deconstruct this pathway in NF1-mutant MPNSTs. There are three Class 1A catalytic PI3K isoforms: p110α, p110β, and p110δ. While p110α is frequently mutated in human cancer, p110β has been shown to play an essential role in PTEN mutant cancers and p110δ is critical in chronic lymphocytic leukemia (18) (19) (20) . To identify which catalytic isoform(s) are essential in NF1-mutant nervous system malignancies, we first assessed the biological effects of isoform-specific ablation in human MPNST cells derived from NF1 patients.
RESULTS
While all three isoforms were present in MPNSTs, genetic ablation of p110α, but not p110β or p110δ, dramatically impaired the proliferation of both tumor lines (Fig 1A) .
Similarly, NF1-mutant GBMs were exclusively sensitive to siRNA-mediated depletion of p110α, but not p110β or p110δ, suggesting that p110α may play a more general role in NF1-deficient cancers (Fig 1A) . To complement these findings, we utilized PI3K isoform-specific inhibitors: the p110α-specific inhibitor A66-(S), the p110β-specific inhibitor AZD-6284, and the p110δ-specific inhibitor CAL-101, as well as GDC-0941, a pan-PI3K inhibitor (21) (22) (23) (24) . The reported specificities of each drug are outlined in Supplementary Table S1 . In human MPNST cell lines, the p110α-specific inhibitor A66-(s) and GDC-0941 potently inhibited the phosphorylation of AKT and S6; however, the p110β-or p110δ-specific inhibitors, AZD-6284 and CAL-101 respectively, did not suppress the phosphorylation of either protein (Fig 1B) . Accordingly, A66-(S) was the only isoform-specific inhibitor that suppressed proliferation in these cells (Fig 1C; p=0.039 in 90-8TLs and p=0.0006 in S462s). Together, these observations suggest that p110α is the primary catalytic subunit responsible for pro-proliferative PI3K signaling in NF1-mutant nervous system malignancies. mTOR functions in two distinct complexes: the rapamycin-sensitive complex mTORC1, which phosphorylates 4E-BP1 and S6 kinase, and the relatively rapamycin-insensitive complex mTORC2, which phosphorylates AKT at serine 473 (25, 26) .
NF1-deficient
MPNSTs have been shown to be sensitive to rapamycin, indicating that mTORC1 plays a role in this tumor type; however, the contribution of mTORC2 activity, if any, to MPNST growth is unknown (13, 17) . We genetically targeted essential component proteins of each complex in order to evaluate the relative contribution of these two complexes.
RAPTOR, is an essential component of mTORC1, but is not present in mTORC2, while RICTOR, a primary component protein of mTORC2, is not a member of the mTORC1 complex (27, 28) As expected, siRNA-mediated-loss of RAPTOR or mTOR suppressed S6 phosphorylation and led to impaired proliferation of MPNST cell lines (Fig 1D) .
However, loss of RICTOR had no effect on MPNST proliferation, despite the effective suppression of phosphorylation of the mTORC2 target AKT (Fig 1D) .
To further evaluate a role for AKT, or lack thereof, tumors cells were treated with the allosteric AKT inhibitor MK-2206 (29) . MK-2206 suppressed the phosphorylation of AKT at S473 and T308, and effectively inhibited AKT kinase activity as confirmed by the loss of TSC2 phosphorylation on T1462 (Fig 1E and Supp Fig. S1 ). However, unlike rapamycin, MK-2206 had no effect on the proliferation of NF1-mutant MPNST cells ( Fig   1E) . The mTOR kinase inhibitor Torin1 inhibits both the mTORC1 and mTORC2 complexes. Notably, Torin1 has been reported to more effectively inhibit mTORC1, as compared to rapamycin, and in particular more potently suppresses 4E-BP1 phosphorylation, as observed in these studies (Fig 1E and Supp Fig. S1 ). Accordingly, Torin1 potently suppressed the proliferation of NF1 mutant cells and did so better than rapamycin (p< 0.02). As noted, both MK-2206 and Torin1 equivalently and potently suppressed AKT phosphorylation and activity, although only Torin1 suppressed MPNST cell proliferation. Moreover, MK-2206 did not enhance the anti-proliferative effects of rapamycin ( Fig 1F) . Taken together, these results suggest that mTORC1 is a critical effector in NF1-mutant cancers and that mTORC2 and AKT are dispensable in these tumor cells.
Selection of an effective PI3K/mTOR pathway inhibitor
These in vitro studies suggested that pan-PI3K inhibitors, p110-specific inhibitors or mTORC1 inhibitors should suppress the growth of NF1-mutant MPNSTs. Therefore, we first evaluated the in vivo effects of GDC-0941 and rapamycin in a genetically engineered mouse MPNST model. Like human MPNSTs, tumors from these animals harbor compound mutations in Nf1 and p53, and develop with an average latency of five months. These MPNSTs are highly aggressive, and mice survive for an average of 10.7 days after tumors are detected, thus recapitulating the aggressive nature of human tumors (30) . As previously shown, rapamycin suppressed the growth of Nf1/p53 mutant MPNSTs (p<0.0001) (13); however, GDC-0941 did so significantly less well (p=0.0021) (Fig 2A) . Notably, the maximum tolerated dose of GDC-0941 (150mg/kg) inhibited the phosphorylation of AKT, S6 and 4E-BP1 in tumors within 1 hour, however these pathways were reactivated within 4 hours after treatment (Fig 2B) . In contrast, rapamycin suppressed S6 and 4E-BP1 phosphorylation for at least 18 hours, consistent with the observed enhanced efficacy and the demonstrated importance of mTORC1 is these tumors. It should be noted that AKT is not activated by relief of feedback mechanisms in this model, as we have previously shown (Fig 2B) (13, 31) . Several other PI3K/mTOR pathway inhibitors including BEZ-235, Torin2, and INK-128 were evaluated in these animals (data not shown); however we were unable to identify an inhibitor that exhibited better pharmacodynamics or growth inhibition than rapamycin at tolerable doses in these animals. Therefore, rapamycin was selected for further studies.
Combined, sustained inhibition of mTORC1 and MEK promote MPNST regression in vivo
Although mTORC1 is a critical signaling node in NF1 mutant tumors, mTORC1 inhibition exerted only cytostatic effects on MPNSTs in vitro and in vivo (Fig 1D, E, 2A ) (13) . Therefore, we evaluated the effects of rapamycin combined with a MEK inhibitor, which targets a second critical RAS effector pathway inhibitor. Tumor-bearing mice were treated with vehicle, the MEK inhibitor PD-0325901, rapamycin, or the combination of rapamycin and PD-0325901. As a monotherapy, PD-0325901 slightly attenuated the growth of MPNSTs, but did so less than rapamycin (Fig 2C) . However, combined PD-0325901 and rapamycin induced tumor regression in these mice (Fig 2C) . Interestingly, these observations differ from effects observed in benign NF1-deficient peripheral (32, 33) . Nevertheless, upon examining the pharmacodynamics of PD-0325901 at this dose, we found that ERK phosphorylation was inhibited for only 4-6 hours, whereas sustained inhibition could be achieved by dosing with PD-0325901 twice daily ( Fig 2D) . As such, we hypothesized that a revised dosing schedule might exert more potent therapeutic effects. Twice-daily PD-0325901 treatment did not promote tumor regression as a monotherapy, however when combined with rapamycin, twice daily PD-0325901 treatment improved the therapeutic response ( tumors from animals treated with vehicle, rapamycin, PD-0325901 (twice daily), or the combination of rapamycin and PD-0325901 were evaluated. Importantly, tissues were collected after 14 hours of treatment: a time point that would capture transcriptional changes caused by sustained target inhibition but occurring prior to tumor regression.
Using a gene expression class comparison, we identified a gene set that was exclusively regulated by combined rapamycin and PD-0325901 treatment (Fig 3A) . Interestingly Slc2a1, which encodes a glucose transporter and is commonly referred to as Glut1, was identified as one of the uniquely suppressed genes in rapamycin/PD901 treated tumors (Fig 3A) Effective mTORC1 and MEK target inhibition in tumor tissue was verified ( Fig   3B) . Q-PCR analysis confirmed that Glut1 levels were reduced 64% after only 14 hours of treatment compared to vehicle treated tumors and that neither rapamycin nor PD-0325901 exerted suppressive effects alone (Fig 3C) . A dramatic decrease in GLUT1 protein levels was further confirmed by evaluating its expression in tumor biopsies taken before and 3 days after treatment (Fig 3D) . These findings differ from observations in VHL and LKB1 mutant tumors, where GLUT1 mRNA and consequently protein expression is primarily regulated by mTOR and HIF1 and its expression can be suppressed by mTORC1 inhibitors alone (34, 35) . However in these Nf1-mutant MPNSTs, suppression of both mTORC1 and the MEK/ERK pathways are required. This finding resolves a longstanding observation that rapamycin is not sufficient to suppress the expression of GLUT1, or other HIF-1 target genes in vitro or in vivo in this tumor type (13) . Together, these results demonstrate that GLUT1 is suppressed in MPNSTs only after combined mTORC1 and MEK inhibition, which could be exploited for developing an imaging biomarker of combined target inhibition.
Research. 
or rapamycin, did not have a significant change in 18 F-FDG uptake after treatment ( Fig   4A,B) ; however, animals treated with both PD-0325901 and rapamycin exhibited a significant decrease in SUVmax values (p<0.004) (Fig 4A,B) . Importantly, while hexokinase and other GLUT genes can regulate glucose uptake in some settings (41, (44) (45) (46) , rapamycin/PD-0325901 treatment did not affect the expression of any of these genes suggesting that GLUT1 may be the rate limiting step for FDG-PET uptake in MPNSTs (Supplemental Table S2 ).
These observations suggested that FDG-PET imaging could be used as a biomarker of effective combined mTORC1/MEK inhibition in NF1-mutant tumors. Such a biomarker would be invaluable in the course of evaluating similar therapies in the clinic and in the course of dose de-escalation/escalation studies. This biomarker would be particularly useful if the early change in FDG-PET imaging were predictive of a later change in tumor size. To experimentally evaluate this possibility, we performed a dose deescalation study in mice. Mice were treated with rapamycin in combination with 100%, 50%, or 25% of the PD-0325901 dose. As expected, this produced a range of responses in FDG-PET uptake at 40 hours and tumor regression after 10 days (Fig. 4C,D) .
Importantly, the suppression of FDG-PET activity at 40 hours, as measured by change in SUVmax, correlated with the ultimate decrease in tumor size after 10 days (Pearson R=0.711, p=0.03) (Fig 4D,E) . These results suggest that early changes in the FDG-PET signal are indicative of the degree of target inhibition and correlate with eventual tumor regression in MPNSTs treated with combined mTORC1/MEK inhibitors.
DISCUSSION
Numerous PI3K pathway inhibitors have been developed and are being evaluated in clinical trials (16) . However in many cancers it is not clear which specific component(s) within this pathway are most critical or to what degree they must be inhibited. Such information would undoubtedly facilitate the selection of the most appropriate drugs for clinical studies. In this study we used a genetic and chemical approach to systematically deconstruct the PI3K signaling pathway in NF1-mutant nervous system malignancies.
Importantly, we found that mTORC1, which is regulated by p110in these tumors, is the minimal, essential PI3K pathway component and that surprisingly AKT and mTORC2 are dispensable. However, while agents that inhibit mTORC1 promote cytostasis in human tumor cells and genetically engineered models, tumor regression requires concomitant suppression of the MEK/ERK pathway.
Notably, there are currently no effective therapies for MPNSTs. As such, these studies reveal a promising therapeutic approach as well as a mechanistic framework for selecting the most appropriate agents for clinical trials. For example, because p110 does not appear to contribute to the therapeutic response in these tumors perhaps p110-specific, -sparing PI3K inhibitors could be used with less toxicity (47) . Alternatively, because mTORC1 appears to be the key PI3K effector in these tumors perhaps rapalogues, which exhibit excellent pharmacokinetic properties, may be suitable for combination therapies.
The observation that AKT is not activated in these tumors by feedback inhibition and that AKT inhibitors do not enhance the effects of rapamycin, further alleviates the concern that AKT suppression may be required in this setting. Nevertheless, these studies suggest that successful agents must promote sustained inhibition of both ERK and mTORC1.
Importantly, suppression of these same targets results in tumor regression in a mouse model of NF1-mutant melanoma, underscoring the importance of these pathways in NF1-deficient cancers (4). Nevertheless, establishing the sufficient degree/length of inhibition of both targets that will be required to mediate an efficacious response in patients represents a formidable challenge.
While mouse models are useful for identifying critical therapeutic targets in genetically defined cancers, the ultimate success of a therapy in humans depends on many factors.
Certainly, species-specific differences in tumor complexity may limit efficacy or restrict therapeutic responses to a subset of patients. However, perhaps an even more important consideration relates to dosing. One of the primary obstacles in developing combination therapies, especially when targeting two major signaling pathways, is achieving efficacy while preventing toxicity. As such, even if the correct therapeutic targets have been identified, it may not be possible to sufficiently suppress these targets in humans. MEK inhibitors have been shown to exhibit toxicity in humans at high doses (48, 49) . Therefore in this study we used a dose of PD-0325901 that is comparable to the tolerable dose in humans. Similarly, the dose of rapamycin was selected based on a previous preclinical study that led to successful human clinical trial in a number of tuberous sclerosis complex related pathologies, although reported trough plasma levels were somewhat higher than what has been observed in humans (~50ng/ml versus 3-20 ng/ml in humans) (50-53). inhibitors. Given the differences in toxicity observed between mice and humans, only clinical trials will reveal whether an effective, non-toxic dose can be achieved. As such, another important goal of this study was to develop a biomarker that could be used to guide dosing in the clinic.
Current clinical trial strategies involve dosing up to the Maximum Tolerated Dose of one drug, and adding the second drug to the tolerable dose when possible. However, it is not always clear how dose escalation/de-escalation affects the degree or kinetics of target inhibition or if dosing at the MTD is necessary. As such, we set out to identify a biomarker(s) that would serve as an early downstream readout of effective, combined inhibition of MEK and TORC1. While several genes were identified in these tumors, GLUT1 stood out as an important and tractable molecular change. Consistent with the documented role of GLUT1 in regulating glucose uptake, we found that 18 F-FDG uptake, as measured by FDG-PET, was a reliable readout of effective, combined target inhibition in vivo. Importantly, changes in GLUT1 expression and 18 F-FDG uptake occurred prior to tumor regression, supporting its role as a molecular marker of TORC1/MEK suppression rather than a consequence of tumor shrinkage. Interestingly, neither GLUT1 expression nor glucose uptake were suppressed after treatment with either rapamycin or MEK inhibitors alone. This observation differs from findings in a subset of other mTOR-driven tumor types, where HIF1α-dependent GLUT1 expression is decreased after treatment with rapamycin, as is 18 F-FDG uptake (34, 35) . We have previously shown that neither 
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Cell Lines and Reagents
S462s and LN229s were purchased from ATCC. 90-8TLs were generously provided by Labs: p120 (G12920), Sigma: Actin (A2066), Alpha Diagnostics: Glut1 (GT11-A).
Torin1, A66-(S), AZD-6284, and CAL-101 were kindly provided by Nathanael Gray (Dana Farber Cancer Institute/Harvard Medical School). MK-2206 was generously provided by D. Wade Clapp (Indiana University). GDC-0941 was provided by Genentech (San Francisco, CA). PD-0325901 was a gift from Kevin Shannon (University of California, San Francisco). Rapamycin was purchased from LC Labs.
RNAi
Non-Targeting and PIK3CA, PIK3CB, PIK3CD, Raptor, Rictor, mTOR siRNA pools were purchased from Dharmacon (D-001810-10, L-003018-00, L-003019-00, L-006775-00, L-004107-00, L-016984-00, L-003008-00, respectively). siRNAs were transfected overnight in antibiotic free medium using RNAiMax lipofectamine from Invitrogen.
Cellular Proliferation Studies
Approximately 125,000 cells per well were seeded in 6-well plates. For siRNA experiments, cells were seeded 12-16 hours after transfection. 24-hours after plating, day 0 counts were taken using a hemocytometer and trypan blue exclusion. For inhibitor experiments, drug treatments were started at this time. Inhibitors were changed once daily, except for PI3K isoform experiments where drugs were replenished twice daily.
Final cell counts were taken 96 hours after day 0 counts.
Drug treatments and dosing schedule
Animal procedures were approved by the Center for Animal and Comparative Medicine in Harvard Medical School in accordance with the NIH Guild for the Care and Use of Laboratory Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously described (30) . Mice were treated daily with rapamycin via IP injections at 5 mg/kg prepared as previously described (13) . PD-0325901 was administered at 1.5
mg/kg once or twice daily (10 hours apart) by oral gavage. PD-0325901 was prepared as previously described. (54) . GDC-0941 was administered at 150mg/kg once daily by oral gavage. GDC-0941 was prepared as previously described (55) . Compounds given in combination were administered sequentially.
Biopsy
Tumor biopsy was taken on mice prior to drug treatment using the wedge biopsy technique and snap-frozen. Drug treatment was started 8 hours after initial biopsy. The post-treatment biopsy was performed 3 days after treatment began. The mouse was anesthetized by isoflurane inhalation and given a local block with lidocaine and marcaine while the tumor biopsy was collected.
Tumor volume measurements
Mice were started on a treatment when tumor size reached 200-1000 mm3. Tumor size was measured every 2-3 days by Vernier calipers. Tumor volume was calculated using the standard formula L x W 2 x 0.52. A mouse pathologist confirmed that all tumors in this study are MPNSTs.
F-FDG-PET imaging and analysis
PET/CT scans were performed on the Bioscan NanoPET/CT at the Longwood Small Animal Imaging Facility. This PET scanner is equipped with a dedicated isoflurane anesthesia system, temperature controlled platform, cardiac gating, and respiratory gating. PET scanning was performed on anesthetized animals lying motionless on a table,
after Retro-orbital IV injection of 0.1 to 10 mCi of F18-FDG PET radioisotope, while being imaged with a coincidence camera. The mice were imaged after a pre-determined "washout" period (30-60 min). Individual mice were first scanned pre-treatment and then
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